The DOI matches its Crossref record; 192 of the 192 references it cites were found in a registry or an index.
Distinct but complementary contributions of PPAR isotypes to energy homeostasis
Open accessAbstract
Peroxisome proliferator-activated receptors (PPARs) regulate energy metabolism and hence are therapeutic targets in metabolic diseases such as type 2 diabetes and non-alcoholic fatty liver disease. While they share anti-inflammatory activities, the PPAR isotypes distinguish themselves by differential actions on lipid and glucose homeostasis. In this Review we discuss the complementary and distinct metabolic effects of the PPAR isotypes together with the underlying cellular and molecular mechanisms, as well as the synthetic PPAR ligands that are used in the clinic or under development. We highlight the potential of new PPAR ligands with improved efficacy and safety profiles in the treatment of complex metabolic disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Stechschulte, L. A., Ge, C., Hinds, T. D., Sánchez, E. R., Franceschi, R. T., & Lecka‐Czernik, B. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.752493 · Cited by 24
RetractedHeinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Type 2 diabetes as an inflammatory disease
Donath, M. Y., & Shoelson, S. E. (2011) · Nature Reviews Immunology · doi:10.1038/nri2925 · Cited by 3,737
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439 · cited 2×
“Fibrate outcome trials such as the Helsinki Heart Study (HHS) (15), Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial (VA-HIT) (16), Bezaf-ibrate Infarction Prevention (BIP) (17), Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) (18), and Action to Control Cardiovascular Risk in D…”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · cited 1×
“However, in humans with NAFLD, PPARγ expression is unaltered (59) and TZD treatment decreases hepatic steatosis, likely due to decreased FA flux from WAT to liver (95, 96).”
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837 · cited 7×
“Several fibrate trials, including FIELD and ACCORD, failed to meet the primary endpoint of reduced CV risk; however, such negative outcomes are likely linked to inappropriate patient selection, since subgroup analyzes revealed significant CV risk reduction in those patients with marked dyslipid-emia upon trial enrolme…”
InfluentialA genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
Scott, L. J., Mohlke, K. L., Bonnycastle, L. L., Willer, C. J., Li, Y., Duren, W. L., Erdos, M. R., Stringham, H. M., Chines, P. S., Jackson, A. U., et al. (2007) · Science · doi:10.1126/science.1142382 · Cited by 2,753
Cited by
PPAR control of metabolism and cardiovascular functions
Montaigne, D., Butruille, L., & Staels, B. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00569-6 · Cited by 942
Self-citationMolecular Actions of PPARα in Lipid Metabolism and Inflammation
Bougarne, N., Weyers, B., Desmet, S. J., Deckers, J., Ray, D. W., Staels, B., & De Bosscher, K. (2018) · Endocrine Reviews · doi:10.1210/er.2018-00064 · Cited by 898
Self-citationThe role of peroxisome proliferator-activated receptors (PPAR) in immune responses
Christofides, A., Konstantinidou, E., Jani, C., & Boussiotis, V. A. (2021) · Metabolism · doi:10.1016/j.metabol.2020.154338 · Cited by 720
Tanase, D. M., Gosav, E. M., Costea, C. F., Ciocoiu, M., Lacatusu, C. M., Maranduca, M. A., Ouatu, A., & Floria, M. (2020) · Journal of Diabetes Research · doi:10.1155/2020/3920196 · Cited by 627
“elevated [53] and that SREBP-1c/PPARα ratio can be used as an index of hepatic steatosis [54].”
BackgroundDysregulated lipid metabolism links NAFLD to cardiovascular disease
Deprince, A., Haas, J. T., & Staels, B. (2020) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101092 · Cited by 554
Self-citationTargeting fibrosis: mechanisms and clinical trials
Zhao, M., Wang, L., Wang, M., Zhou, S., Lu, Y., Cui, H., Racanelli, A. C., Zhang, L., Ye, T., Ding, B., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01070-3 · Cited by 547
Myricetin: A review of the most recent research
Song, X., Tan, L., Wang, M., Ren, C., Guo, C., Yang, B., Ren, Y., Cao, Z., Li, Y., & Pei, J. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111017 · Cited by 378
Lefere, S., Puengel, T., Hundertmark, J., Penners, C., Frank, A. K., Guillot, A., de Muynck, K., Heymann, F., Adarbes, V., Defrêne, E., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.04.025 · Cited by 310
“8,27 To con fi rm this mode of action, we tested the anti-steatotic ef fi cacy of lani fi branor in vitro .”
PPAR Agonists and Metabolic Syndrome: An Established Role?
Botta, M., Audano, M., Sahebkar, A., Sirtori, C., Mitro, N., & Ruscica, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041197 · Cited by 253
PPARs as Nuclear Receptors for Nutrient and Energy Metabolism
Hong, F., Pan, S., Guo, Y., Xu, P., & Zhai, Y. (2019) · Molecules · doi:10.3390/molecules24142545 · Cited by 233
“Similar to PPARα, PPARβ/δ facilitates the oxidation of fatty acids in the liver, WAT, and SKM, and it also lowers the levels of very-low-density lipoproteins (VLDLs) and TGs in plasma, but increases the HDL levels in serum [34].”
BackgroundInfluentialNovel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Clostridium ramosum regulates enterochromaffin cell development and serotonin release
Mandić, A. D., Woting, A., Jaenicke, T., Sander, A., Sabrowski, W., Rolle-Kampcyk, U., von Bergen, M., & Blaut, M. (2019) · Scientific Reports · doi:10.1038/s41598-018-38018-z · Cited by 150
Yu, G., Jin, M., Huang, Y., Aimuzi, R., Zheng, T., Nian, M., Tian, Y., Wang, W., Luo, Z., Shen, L., et al. (2021) · Environment International · doi:10.1016/j.envint.2021.106621 · Cited by 141
Hong, F., Xu, P., & Zhai, Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19082189 · Cited by 139
Breakthroughs in therapies for NASH and remaining challenges
Ratziu, V., Francque, S., & Sanyal, A. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.04.002 · Cited by 132
Berthier, A., Johanns, M., Zummo, F. P., Lefebvre, P., & Staels, B. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2021.166097 · Cited by 125
“Hepatic PPAR activity is mainly determined by i) agonist availability, ii) their relative expression levels across cell types, iii) the cell-specific epigenomic and transcriptional machinery, iv) the nutritional status, v) circadian rhythms and vi) sexual dimorphism [7,8].”
BackgroundInfluentialSelf-citationLefebvre, P., Lalloyer, F., Baugé, E., Pawlak, M., Gheeraert, C., Dehondt, H., Vanhoutte, J., Woitrain, E., Hennuyer, N., Mazuy, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.92264 · Cited by 117
Self-citationDeciphering the decline of metabolic elasticity in aging and obesity
Zhou, Q., Yu, L., Cook, J. R., Qiang, L., & Sun, L. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.08.001 · Cited by 80
Lipid Lowering Drugs: Present Status and Future Developments
Ruscica, M., Ferri, N., Santos, R. D., Sirtori, C. R., & Corsini, A. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00918-3 · Cited by 73
Impact of PPAR-Alpha Polymorphisms—The Case of Metabolic Disorders and Atherosclerosis
Ruscica, M., Busnelli, M., Runfola, E., Corsini, A., & Sirtori, C. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20184378 · Cited by 33
Advancing care in primary biliary cholangitis: emerging insights and novel therapies
Vögelin, M., & Kremer, A. E. (2025) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2025.2516622 · Cited by 5
“Pharmacological PPAR may be isoform-selective (e.g. PPAR α agonists) or pan-PPARs that activate multiple subtypes simultaneously [43].”
Metadata
- Authors
- Dubois, V., Eeckhoute, J., Lefebvre, P., & Staels, B.
- Venue
- Journal of Clinical Investigation
- Published
- 2017-04-03
- Volume
- 127
- Issue
- 4
- Pages
- 1202-1214
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- OpenAlex
- W2602059628
- Cited by
- 383
- References
- 192
- FWCI
- 10.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.